Galangin, Galanal A, and α-Farnesene as Anticancer Candidates for Breast Cancer: A Molecular Docking Study: Galangin, Galanal A, dan α-Farnesene sebagai Kandidat Antikanker Kanker Payudara: Kajian Molecular Docking

Gumilang Mutiara Hilia (Biologi Education Program, Faculty of Teacher Training and Education, Muhammadiyah University of Jember, Jember, Indonesia)
Indah Rakhmawati Afrida (Biologi Education Program, Faculty of Teacher Training and Education, Muhammadiyah University of Jember, Jember, Indonesia)
Aulya Nanda Prafitasari (Biologi Education Program, Faculty of Teacher Training and Education, Muhammadiyah University of Jember, Jember, Indonesia)

Jurnal Ilmiah Biologi Eksperimen dan Keanekaragaman Hayati (J-BEKH)
Vol. 13 No. 1 (2026): June Edition

Breast cancer is one of the leading causes of cancer-related deaths among women worldwide. The development of anticancer agents derived from natural compounds continues to be explored due to their high bioactive potential and relatively low toxicity. This study aims to evaluate the anticancer potential of Galangin, Galanal A, and α-Farnesene derived from Alpinia purpurata against breast cancer using an in silico approach. Molecular docking was conducted to analyze binding affinity and residue interactions between the test compounds and the target protein. The docking results showed that Galangin had the lowest binding energy at -235.43 cal/mol, followed by Galanal A (-206.01 cal/mol) and α-Farnesene (-196.48 cal/mol), indicating stable interactions. All three compounds interacted with key residues such as PHE71, LYS75, and GLU68 within the active site of the target protein. Galangin exhibited the highest binding affinity and the greatest number of interacting residues, making it the most promising candidate for inhibiting breast cancer. These findings suggest that Galangin, Galanal A, and α-Farnesene have potential as anticancer agents against breast cancer and warrant further investigation through experimental studies.